Research shows that the Janssen Ad26.COV2.S COVID-19 Vaccine by Johnson and Johnson causes an increased rate of cerebral venous sinus thrombosis (CSVT).
The study was peer-reviewed by published in the Journal of American Medical Association this month.
Cerebral sinus thrombosis (CSVT) happens when blood clots form in the dural sinuses of the brain. Dural sinuses drain blood from the brain back into the systemic circulation. If a clot forms in the sinuses, the blood backs up, pressure increases, and a high risk of bleeding into the brain.
It is a medical emergency due to the increased risk of death. The image below shows the dural sinuses in blue.
Infection, active cancer, and oral contraceptives are risk factors that make a person prone to developing CSVT.
To establish a baseline or pre-pandemic level of CSVT, the authors looked at the number of CSVT cases in Olmsted County, Minnesota. From 2001 through 2015, 39 patients developed acute CSVT. Twenty-nine of them had predisposing risk factors.
Next, the study obtained the CSVT cases from the CDC Vaccine Adverse Reporting System VAERS to count the number of CSVT from February 28, 2021, to May 07, 2021.
Then, the authors compared the incidence of CSVT among people injected with the Janssen vaccine to the pre-pandemic levels.
Results
This year there were 38 confirmed diagnoses of CSVT within 92 days after receiving the Janssen vaccine.
27 out of 38 were female. The median age is 45 years (range, 19-75 years).
The median time from vaccination to CVST was nine days (range 1-51 days).
31 of 38 cases of CVST (81.6%) occurred within 15 days after vaccination.
36 or (94.7%) occurred within 30 days.
How did the results compare to the pre-pandemic levels?
The postvaccination CVST rate among females was 5.1-fold higher
compared with the pre-COVID-19 pandemic rate (13.01 vs. 2.53 per
100,000 person-years).
This risk was highest among women aged 40 to 49 years, followed by 30 to 39 years.
Another study shows csvt rate is higher!
The authors cited another study printed in the journal Stroke in 2016. That investigation showed that the pre-pandemic level of CSVT is lower compared to this study. (0.22-1.57per 100,000 person-years) [2]
Comparing the incidence of the present study (13.01 per 100,000 person-years) to the 2016 study (0.22-1.57 per 100,000 person-years) will show the risk of developing CSVT with the Janssen COVID-19 vaccine is 59.13 to 8.28 higher than pre-pandemic levels!!
The concerning part is that it is higher.
The CSVT cases in the 2021 study were obtained from the VAERS. What do we know about the VAERS system? The adverse events are massively underreported in VAERS. By how much?
Harvard Pilgrim Health Care did an investigation to study the accuracy of VAERS in 2011. They came out with the Lazarus Report named after the principal investigator, Ross Lazarus.
What they found is that the adverse events are underreported. Here is part of the report. (Emphasis added).
Although 25% of ambulatory patients experience an adverse drug event, less than 0.3% of all adverse drug events and 1-13% of serious events are reported to the Food and Drug Administration (FDA).
Likewise, fewer than 1% of vaccine adverse events are reported.
Therefore, multiply the number of CSVT cases by 100, and you will get to the actual number of CSVT.
The other COVID vaccines also cause CSVT
The Johnson and Johnson COVID-19 Vaccine is not the only vaccine that can cause CSVT. CSVT has been reported in the Astra-Zeneca here and here. Pfizer Biontech thrombosis was reported here. And Moderna here.
Would you agree that pulling all these vaccines off the market is way overdue?
If you know someone who had the COVID shots, they should read this article and Know the Signs of Vaccine-Induced Blood Clotting.
Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like.
Don’t Get Sick!
If you find value in the articles, please consider a donation to show your support.
Related articles
- You Have to Know Vaccine Related Kounis Syndrome
- Myocarditis after mRNA Vaccination in the Military
- Unidentified Foreign Bodies in the Vaccines Form Clots
- What Happens to Patients, Doctors, and Big Pharma in Adverse Drug Reactions?
- CDC Report shows 25% Mortality in Breakthrough Cases
- UK Data shows more COVID-19 ER visits and Deaths Among the Vaccinated
- Shingles after COVID-19 Vaccination
- The Durability Study of the Moderna COVID-19 Vaccine is Strange and Unusual
- Durable Immunity from Pfizer COVID-19 Vaccine Lasts only Six Months
- Can Breathing spread the Spike Protein?
- Molecular mimicry between the spike protein and humans can shut down platelet production
- Platelet Changes Causes Blood Clots in COVID-19
References:
- Ashrani et al. Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination. JAMA Intern Med. Published online November 01, 2021. doi:10.1001/jamainternmed.2021.6352
- Devasagayam et al. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke. 2016;47(9):2180-2182. doi:10.1161/STROKEAHA.116.013617
© 2018 – 2021 Asclepiades Medicine, L.L.C. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases.